Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines

Exec Edge

04-22

By Karen Roman

Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.

The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.

“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”

Contact:

Exec Edge

Editor@executives-edge.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2529511553"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529511553\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2529511553?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-22 06:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2529511553","market":"us","top_or_hot":-1,"title":"Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines","media":"Exec Edge","content":"<html><body><p><img height=\"622\" src=\"https://s.yimg.com/uu/api/res/1.2/PIbClYX6PcGlghj8ID4Ecw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a9b4020d2d39b696347c9b250ff7f00f\" width=\"932\"/></p>\n<p>By Karen Roman</p>\n<p>Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.</p>\n<p>The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.</p>\n<p>“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”</p>\n<p>Contact:</p>\n<div>\nExec Edge\n</div>\n<div>\n<p>Editor@executives-edge.com</p>\n</div></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Exec Edge</strong><span class=\"h-time small\">2025-04-22 06:10</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><img height=\"622\" src=\"https://s.yimg.com/uu/api/res/1.2/PIbClYX6PcGlghj8ID4Ecw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a9b4020d2d39b696347c9b250ff7f00f\" width=\"932\"/></p>\n<p>By Karen Roman</p>\n<p>Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.</p>\n<p>The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.</p>\n<p>“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”</p>\n<p>Contact:</p>\n<div>\nExec Edge\n</div>\n<div>\n<p>Editor@executives-edge.com</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/ascentage-pharma-drugs-included-chinese-221005131.html\">Exec Edge</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BDGV0183.EUR","symbol_name":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-drugs-included-chinese-221005131.html","article_id":"2529511553","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529511553","pubTimestamp":1745273405,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Ascentage Pharma Group Internat  said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology  Guidelines.The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.“The recommendations for both olverembatinib and lisaftoclax  in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4515":"5G概念","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK4139":"生物科技","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001424.SGD":"United E-Commerce Fund SGD","BK4525":"远程办公概念","LU1046421795.USD":"富达环球科技A-ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","CSCO":"思科","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","BK4527":"明星科技股","BK4020":"通信设备","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","BK4588":"碎股","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","BK4550":"红杉资本持仓","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","AAPG":"亚盛医药","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC"},"translate_title":"亚盛医药药物纳入中国临床肿瘤学会指南","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAPG":0.9,"CSCO":1},"content_text":"By Karen Roman\nAscentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.\nThe added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.\n“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”\nContact:\n\nExec Edge\n\n\nEditor@executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}